TEVA
Teva Pharma Industries Ltd ADR
NYSE: TEVA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$35.38
+11.89% today
Updated 2026-04-29
Market cap
$41.20B
P/E ratio
26.40
P/S ratio
2.39x
EPS (TTM)
$1.34
Dividend yield
—
52W range
$15 – $37
Volume
6.7M
WallStSmart proprietary scores
68
out of 100
Grade: B
Buy
Investment rating
6.7
Growth
B4.8
Quality
C7.5
Profitability
B+6.7
Valuation
B6/9
Piotroski F-Score
Moderate
0.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$38.27
+8.17%
12-Month target
$29.25
-17.33%
Intrinsic (DCF)
$63.58
Margin of safety
+46.04%
4 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ ROE 20.80% — strong efficiency
+ Free cash flow $1.02B — positive
+ Revenue growth 11.40% QoQ
+ 46.04% below intrinsic value
Risks
- Altman Z 0.28 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $14.93B | $15.85B | $16.54B | $17.26B | $17.26B | $17.1B |
| Net income | $-2.45B | $-559.00M | $-1.64B | $1.41B | $480.00M | — |
| EPS | — | — | — | — | $1.34 | $2.76 |
| Free cash flow | $1.04B | $842.00M | $749.00M | $1.15B | $1.02B | — |
| Profit margin | -16.39% | -3.53% | -9.91% | 8.17% | 8.17% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-17 | SABAG, MARK | Sale | 62,102 | $30.14 |
| 2026-03-05 | WEISS, AMIR | Sale | 3,537 | — |
| 2026-03-05 | WEISS, AMIR | Buy | 3,537 | — |
Peer comparison
Smart narrative
Teva Pharma Industries Ltd ADR trades at $35.38. representing a P/E of 26.40x trailing earnings. Our Smart Value Score of 68/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 0.28, it sits in the distress. TTM revenue stands at $17.26B. with profit margins at 8.17%. Our DCF model estimates intrinsic value at $63.58.
Frequently asked questions
What is Teva Pharma Industries Ltd ADR's stock price?
Teva Pharma Industries Ltd ADR (TEVA) trades at $35.38.
Is Teva Pharma Industries Ltd ADR overvalued?
Smart Value Score 68/100 (Grade B, Buy). DCF value $63.58.
What is the price target of Teva Pharma Industries Ltd ADR (TEVA)?
The analyst target price is $38.27, representing +8.2% upside from the current price of $35.38.
What is the intrinsic value of Teva Pharma Industries Ltd ADR (TEVA)?
Based on our DCF model, intrinsic value is $63.58, a +46.0% margin of safety versus $35.38.
What is the future stock price of TEVA by 2030?
Our research-backed model estimates Teva Pharma Industries Ltd ADR could reach $216.58 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Teva Pharma Industries Ltd ADR's revenue?
TTM revenue is $17.26B.
Piotroski F-Score?
6/9 — moderate financial health.
Altman Z-Score?
0.28 — distress.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.39x
ROE20.80%
Beta0.76
50D MA$31.22
200D MA$25.69
Shares out1.16B
Float1.07B
Short ratio—
Avg volume6.7M
Performance
1 week+15.47%
1 month+16.96%
3 months+3.81%
YTD+13.36%
1 year—
3 years—
5 years—